Jim Cramer talked about oil, Citigroup (C), burger joints and biotechs when answering viewer questions from social media on Friday. Cramer said oil continues to weigh on the market, and that oil will be lower for longer. Cramer said Citigroup reported a good quarter, and it sells at a discount to its book value, but in the current market environment, it’s hard for stocks to rise. A viewer asked if consumers will stop buying expensive burgers if the U.S. economy slows, and asked Cramer’s opinion on Red Robin (RRGB). Cramer said he likes Jack in the Box (JACK) and Panera (PNRA) in the restaurant group, along with Starbucks (SBUX). Cramer also discussed Chipotle (CMG), Shake Shack (SHAK) and Darden (DRI). Another viewer asked whether Home Depot (HD) is a buy. Cramer said Home Depot and Kroger (KR) are two of his favorite stocks, but he’s not buying them now due to the bear market. Cramer also said stocks like Novavax (NVAX) and other biotechs are falling on negative news from Sarepta (SRPT), but a stock like Novavax is good for a young investor with a long time horizon. Cramer is portfolio manager of Action Alerts PLUS. Send your questions to Cramer’s Facebook (FB) page or find him on Twitter (TWTR). Use hashtag Cramer Q.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.